Introduction {#Sec1}
============

The role of rotational atherectomy (RA) in contemporary percutaneous coronary interventions (PCI) is expanding, especially with extension of PCI to more challenging anatomical settings \[[@CR1]\]. Severely calcified coronary lesions exist in 6--20% of PCI patients \[[@CR2], [@CR3]\]. Calcification makes PCI more complex and increases the risk of complications such as stent under-expansion, restenosis, target lesion revascularization, myocardial infarction (MI), and death \[[@CR4], [@CR5]\]. Another challenge for PCI arises from reduced left ventricular ejection fraction (LVEF), which has an adverse effect on acute and long-term outcomes \[[@CR6], [@CR7]\].

RA was historically not recommended in patients with impaired LV function due to inherent acute cardio-depressive effects \[[@CR8]\]. Contemporary RA practice tends to modify calcified plaques by using smaller burrs and lower rotational speeds rather than aggressive debulking of the lesion. The modern approach is assumed to cause less vessel injury and microvascular obstruction \[[@CR9]\] and could therefore be a safer strategy in patients with impaired LV function. Additionally, the expanding use of percutaneous mechanical circulatory support (PMCS) facilitates PCI in complex anatomies and unstable hemodynamic settings and/or impaired LV function \[[@CR10]\].

The aim of this analysis is to investigate the outcomes of RA in patients with reduced LVEF.

Methods {#Sec2}
=======

Study Design and Patients {#Sec3}
-------------------------

This is a retrospective analysis of patients who underwent RA at a single tertiary center (Heart Centre, Segeberger Kliniken, Bad Segeberg, Germany) between November 2002 and February 2018. Written informed consent was obtained from all patients for analysis of their anonymized data, and data collection was approved by the local ethics committee (Segeberger Kliniken, Bad Segeberg, Germany). The study conforms with the Helsinki Declaration of 1964, as revised in 2013, concerning human and animal rights.

Out of 740 consecutive patients that underwent RA in that time period, 91 presenting with MI and five with no baseline LVEF measurement were excluded. The remaining patients were divided into three groups based on LVEF: severely reduced LVEF ≤ 35%, moderately reduced LVEF 36--54%, and preserved LVEF ≥ 55%. The study flowchart is shown in Fig. [1](#Fig1){ref-type="fig"}. Echocardiography assessment was according to guidelines utilizing the biplane Simpson's method \[[@CR11]\] and was confirmed by LV angiography. Clinical follow-up was obtained either by on-site clinical visit or scripted telephone interview with the patients or their general practitioners.Fig. 1Study flowchart. *MI* myocardial infarction, *LVEF* left ventricular ejection fraction

Procedural Details and Medical Interventions {#Sec4}
--------------------------------------------

RA was applied in severely calcified lesions according to the operator discretion as either primary or a bailout strategy in lesions that were uncrossable by balloons or stents. Technical details of RA at our institution have been previously reported \[[@CR9], [@CR12]\]. Briefly, for all cases, RA was performed using the CE-marked Rotablator device (Boston Scientific Scimed Inc., Maple Grove, MN, USA). The burr size was selected aiming at a burr/vessel ratio of 0.5 (max. 0.7 if needed) and rotational speed was 140,000--180,000 rotations per minute (rpm). To prevent slow flow, a continuous intracoronary infusion of unfractionated heparin (UFH), nitroglycerine, and verapamil was used during RA. Prior to RA, patients were treated with 325--500 mg aspirin orally and an oral loading dose of a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and peri-procedural anticoagulation with either UFH or bivalirudin was routinely administered. The use of glycoprotein IIb/IIIa inhibitors and PMCS \[e.g., with an intra-aortic balloon pump or the Impella system (Abiomed Inc., Danvers, MA, USA)\] was at the operator's discretion.

Endpoint Definitions {#Sec5}
--------------------

Angiographic failure was defined as residual stenosis of ≥ 30% and/or less than residual thrombolysis in myocardial infarction (TIMI) III flow at the end of the procedure. Spontaneous MI as well as peri-procedural MI were defined according to the third universal definition of MI \[[@CR13]\]. Coronary dissection was defined as any dissection requiring additional stenting beyond the primary lesion. Target vessel revascularization (TVR) was defined as any repeated PCI or coronary bypass of the target vessel. Major adverse cardiac events (MACE) were defined as the composite endpoint of all-cause death, MI, and TVR.

Statistical Analysis {#Sec6}
--------------------

Qualitative variables are summarized as frequencies and percentages, while quantitative variables are summarized as mean ± SD or median \[25th--75th quartiles\], depending on variable distribution. Inter-group comparisons were conducted using ANOVA test or Kruskal--Wallis test for continuous variables and by Chi-square test for categorical variables. Survival curves were created using the Kaplan--Meier method, and compared using log rank and Cox hazard regression analyses. For the latter, the hazard ratio (HR) and the 95% confidence interval (CI) are presented. Multivariable binary logistic regression analysis and multivariable Cox regression analysis were performed using entry criteria of *p* \< 0.1 in univariable analysis. Data analysis was performed using SPSS V.24.0 (IBM Corp., New York, NY, USA).

Results {#Sec7}
=======

The mean age of the population was 72.3 ± 8.6 years, 75% were males, and LVEF was 52 ± 13%. LVEF was severely reduced in 82 patients (12.7%), moderately reduced in 170 (26.4%), and preserved in 392 (60.9%). The average LVEF in the three groups was 28.9, 46.5, and 60.9%, respectively.

Demographic and Procedural Characteristics {#Sec8}
------------------------------------------

Patients with severely and moderately reduced LVEF were more likely to have three-vessel coronary artery disease (*p* \< 0.001) with a higher prevalence of chronic renal impairment (*p* \< 0.001), history of MI (*p* \< 0.001), history of PCI (*p* = 0.043), and history of coronary artery bypass grafting (CABG, *p* \< 0.001). Patients' characteristics are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Patients and demographic characteristicsLVEF ≤ 35% (*n* = 82 patients)LVEF 36--54% (*n* = 170 patients)LVEF ≥ 55% (*n* = 392 patients)*p* valueAge, years72.5 ± 8.772.93 ± 8.371.9 ± 8.40.813Male64 (78.0%)128 (75.3%)288 (73.5%)0.664BMI, kg/m^2^27.2 ± 4.427.9 ± 5.027.8 ± 4.70.546LV. Ejection fraction %28.9 ± 5.846.5 ± 3.860.9 ± 4.4\< 0.001Clinical presentation0.207 Chronic stable angina76 (92.7%)144 (84.7%)341(87.0%) Unstable angina6 (7.3%)26 (15.3%)51 (13%)Number of diseased vessels\< 0.001 One7(8.5%)15 (8.8%)77 (19.6%) Two19 (23.2%)39 (22.9%)124 (31.6%) Three56 (68.3%)116 (68.2%)191 (48.7%)Diabetes mellitus26 (32.1%)64 (37.6%)133 (34.1%)0.620Arterial hypertension73 (90.1%)161 (94.7%)349 (89.5%)0.136Dyslipidemia50 (61.7%)119 (70.1%)251 (64.4%)0.323Smoking27 (33.3%)47 (27.6%)127 (32.6%)0.473Familial history175 (18.5%)33 (19.4%)100 (25.6%)0.159Chronic renal impairment (GFR \< 60)19 (32.2%)40 (24.4%)42 (11%)\< 0.001Previous MI27 (32.9%)56 (32.9%)50 (12.8%)\< 0.001Previous PCI43 (52.4%)68 (40.0%)147 (37.5%)0.043Previous CABG327 (32.9%)49 (28.8%)57 (14.5%)\< 0.001Data are shown as number (percentage), mean ± standard deviation*BMI* body mass index, *LV* left ventricle, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting

Target lesions within the reduced LVEF groups were more often ostial (*p* = 0.012), and patients more frequently received PMCS during PCI (*p* \< 0.001). Lesion and procedural characteristics are shown in Table [2](#Tab2){ref-type="table"}.Table 2Lesions and procedural characteristicsLVEF ≤ 35%, (*n* = 89 lesions)LVEF 36--54%, (*n* = 184 lesions)LVEF ≥ 55%, (*n* = 421 lesions)*p* valueTarget vessel Left main12 (13.5%)30 (16.3%)40 (9.5%)0.051 Left anterior descending29 (32.6%)74 (40.2%)219 (52.0%)0.001 Left circumflex18 (20.2%)27 (14.7%)43 (10.2%)0.023 Right coronary artery30 (33.7%)53 (28.8%)119 (28.3%)0.587 Ad hoc PCI10 (11.2%)22 (12.0%)59 (14.0%)0.673 Chronic total occlusion9 (10.1%)19 (10.3%)23 (5.5%)0.061 Bifurcation lesion33 (37.1%)72 (39.1%)168 (39.9%)0.882 Ostial lesion28 (31.5%)57 (31%)89 (21.1)0.012 ACC/AHA type B2/C\*83 (93.3%)162 (88.0%)370 (87.9%)0.366 Predilatation80 (90.9%)163 (88.6%)375 (89.9)0.815Burr sizes0.188 1.2520 (24.1%)47 (26.1%)103 (24.9%) 1.546 (52.9%)71 (39.4%)196 (47.3%) 1.7515 (17.2%)53 (29.4%)88 (21.3%) 24 (4.6%)9 (5.0%)26 (6.3%) 2.251 (1.1%)0 (0.0%)1 (0.2%)More than 1 burr13 (14.8%)23 (12.5%)73 (17.5%)0.289Burr/artery ratio0.49 ± 0.110.50 ± 0.090.51 ± 0.100.292Number of implanted stents1.85 ± 1.31.77 ± 0.101.92 ± 0.980.278Stent diameter3.0 ± 0.543.1 ± 0.473.0 ± 0.490.429Total stent length per lesion24 \[18-40\]30 \[18--46\]32 \[22-48\]0.131Post dilatation59 (67.0%)115 (62.8%)260 (63.6%)0.787Maximum post-dilatation balloon size3.5 ± 0.53.5 ± 0.63.4 ± 0.50.485Type of stent BMS3 (3.4%)21 (11.4%)28 (6.7%)0.036 Early generation DES28 (31.5%)83 (45.1%)173 (41.2%)0.098 New-generation DES56 (62.9%)79 (42.9%)226 (53.8%)0.004 Glycoprotein IIb/IIIa inhibitor usage0 (0.0%)4 (2.2%)11 (2.6%)0.309 Percutaneous hemodynamic assist devices7 (7.9%)1 (0.5%)2 (0.5%)\< 0.001Impella201IABP411Impella and IABP100Elective usage of percutaneous hemodynamic assist devices5(6.1%)1(0.6%)0(0%)\< 0.001Procedural duration (min)82 \[54--109\]68 \[49--94\]72 \[53--98\]0.499Amount of contrast material200 \[120--300\]200 \[150--280\]200 \[150--280\]0.755Data are shown as number (percentage), median \[interquartile range\], mean ± standard deviation*PCI* percutaneous coronary intervention, *\* B2/C* according to ACC/AHA classification, *BMS* bare metal stent, *DES* drug-eluting stent, *IABP* intra aortic balloon pump

Procedural Outcomes {#Sec9}
-------------------

Patients with severely reduced LVEF had a higher rate of angiographic failure as compared to patients with preserved LVEF \[12.2 vs. 3.3%; odds ratio (OR): 4.05, 95% confidence interval (CI) 1.71--9.59, *p* = 0.001\]. This was driven by more frequent residual stenosis ≥ 30% (8.5 vs. 2%; OR: 4.48, 95% CI 1.58--12.73, *p* = 0.005) and slow flow (11 vs. 2%; OR: 5.92, 95% CI 2.21--15.84, *p* \< 0.001). On the other hand, patients with moderately reduced LVEF did not have an increased rates of angiographic failure as compared to patients with preserved LVEF (6.5 vs. 3.3%; OR: 2.02, 95% CI 0.89--4.60, *p* = 0.10). Procedural outcomes are shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Procedural outcomes. *LVEF* left ventricular ejection fraction

On multivariate analysis, angiographic failure was associated with severely reduced LVEF group (OR: 3.36, 95% CI 1.23--9.22, *p* = 0.018) as well as CTO interventions (OR: 2.96, 95% CI 1.04--8.46, *p* = 0.043 (Table [3](#Tab3){ref-type="table"}).Table 3Independent predictors of angiographic failureUnivariateMultivariateOdds ratio95% confidence interval*p* valueOdds ratio95% confidence interval*p* valueLVEF ≤ 35%4.051.71--9.590.0013.361.23--9.22**0.018**LVEF 36--54%2.0170.89--4.600.0951.860.71--4.850.205Chronic renal impairment0.850.32--2.250.744Two-vessel coronary artery disease2.940.68--12.740.150Three-vessel coronary artery disease3.420.75--15.60.112Previous MI1.600.75--3.410.227Previous PCI2.091.05--4.170.0361.350.59--3.080.474Previous CABG1.3410.61--2.930.463Target vessel Left main0.380.09--1.620.192 Left anterior descending1.050.53--2.080.884 Left circumflex1.500.69--3.290.310 Chronic total occlusion2.821.11--7.170.0302.961.04--8.46**0.043** Ostial lesion0.480.18--1.250.132 New-generation DES2.240.93--5.420.0731.960.79--4.840.146*MI* myocardial infarction, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *DES* drug-eluting stent

In-Hospital MACE {#Sec10}
----------------

The rate of in-hospital MACE was 9.8, 3.5, and 2.3% in patients with LVEF ≤ 35, 36--54, and ≥ 55%, respectively (*p* = 0.004). Compared to patients with preserved LVEF, in-hospital MACE was significantly higher in patients with severely reduced LVEF (OR: 4.60, CI 1.72--12.31, *p* = 0.002) and the difference was driven by more peri-procedural MI (6.1 vs. 1.5%; OR: 4.17, 95% CI 1.24--14.03, *p* = 0.021) with a trend towards higher mortality (2.4 vs. 0.5%, *p* = 0.082). On the other hand, patients with moderately impaired LVEF did not show increased rates of in-hospital MACE (*p* = 0.405) in comparison to patients with preserved LVEF. The incidence of in-hospital MACE and its components is displayed in Fig. [3](#Fig3){ref-type="fig"}. On multivariate analysis, severely reduced LVEF was the only independent risk factor for in-hospital MACE (OR: 4.39, 95% CI 1.63--11.81, *p* = 0.003) (Table [4](#Tab4){ref-type="table"}).Fig. 3In-hospital MACE. *MACE* major adverse cardiac events, *MI* myocardial infarction, *TVR* target vessel revascularization, *LVEF* left ventricular ejection fractionTable 4Independent predictors of in-hospital MACEUnivariateMultivariateOdds ratio95% confidence interval*p* valueOdds ratio95% confidence interval*p* valueLVEF ≤ 35%4.601.72--12.310.0024.391.63--11.81**0.003**LVEF 36--54%1.560.55--4.450.4081.450.50--4.170.494Chronic renal impairment1.090.36--3.260.882Two-vessel coronary artery disease4.1640.54--31.920.170Three-vessel coronary artery disease3.920.48--32.330.204Previous MI1.080.39--2.970.880Previous PCI1.170.50--2.700.722Previous CABG1.060.39--2.910.910Target vessel Left main0.300.04--2.170.228 Left anterior descending0.910.39--2.080.814 Left circumflex0.890.30--2.660.831 Chronic total occlusion2.790.91--8.540.0732.490.79--7.820.119 Ostial lesion0.610.21--1.830.380 New-generation DES0.700.27--1.850.476*MI* myocardial infarction, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *DES* drug-eluting stent

Evolution of Procedural Outcomes and In-Hospital MACE over the Study Period {#Sec11}
---------------------------------------------------------------------------

In order to investigate the effect of the time factor over the rates of procedural outcomes, patients were divided chronologically into four quartiles according to the timing of the indexed procedures. No significant difference was found between different periods in term of the rates of procedural outcomes as well as in-hospital MACE (Supplementary Table 2).

The distribution of baseline characteristics over the time quartiles are shown in Supplementary Table 1.

MACE at Five Years {#Sec12}
------------------

The rate of MACE at 5 years was higher in patients with severely reduced LVEF, driven by a higher rate of all-cause death. There was no significant difference across the LVEF groups regarding the rates of MI and TVR (Fig. [4](#Fig4){ref-type="fig"}). On multivariate analysis, MACE was no longer significantly associated with severely reduced LVEF (HR: 1.26, 95% CI 0.80--1.99, *p* = 0.310) but rather with chronic renal impairment (HR: 1.50, 95% CI 1.01--2.23, *p* = 0.045) left anterior descending (LAD) artery as the target vessel during the index procedure (HR: 0.68, 95% CI 0.48--0.95, *p* = 0.025) (Table [5](#Tab5){ref-type="table"}). On the other hand, severely reduced LVEF (HR: 2.57, 95% CI 1.38--4.79, *p* = 0.003) as well as in moderately reduced LVEF patients (HR: 1.95, 95% CI 1.15--3.29, *p* = 0.013) and chronic renal impairment (HR: 3.53, 95% CI 2.13--5.82, *p* \< 0.001) remained independent predictors of all-cause death (Table [6](#Tab6){ref-type="table"}).Fig. 4**a** Kaplan--Meier curve for the cumulative incidence of MACE. **b** Kaplan--Meier curve for the cumulative incidence of all cause death. **c** Kaplan--Meier curve for the cumulative incidence of MI. **d** Kaplan--Meier curve for the cumulative incidence of TVRTable 5Independent predictors of 5-year MACEUnivariateMultivariateHazard ratio95% confidence interval*p* valueHazard ratio95% confidence interval*p* valueLVEF ≤ 35%1.561.01--2.420.0471.260.80--1.990.310LVEF 36--54%1.421.02--1.970.0401.210.86--1.710.279Chronic renal impairment1.571.06--2.310.0231.501.01--2.23**0.045**Two-vessel coronary artery disease1.150.74--1.780.534Three-vessel coronary artery disease1.040.64--1.700.866Previous MI1.280.91--1.790.151Previous PCI0.9470.70--1.290.727Previous CABG1.240.87--1.750.225Target vessel Left main0.920.59--1.430.696 Left anterior descending0.610.45--0.830.0010.680.48--0.95**0.025** Left circumflex1.451.02--2.050.0391.080.72--1.640.699 Chronic total occlusion1.190.66--2.140.563 Ostial lesion1.561.14--2.130.0061.260.90--1.780.183 New-generation DES0.780.56--1.100.159*MI* myocardial infarction, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *DES* drug-eluting stentTable 6Independent predictors of 5-year all-cause deathUnivariateMultivariateHazard ratio95% confidence interval*p* valueHazard ratio95% confidence interval*p* valueLVEF ≤ 35%3.081.67--5.67\< 0.0012.571.38--4.79**0.003**LVEF 36--54%2.191.31--3.660.0031.951.15--3.29**0.013**Chronic renal impairment3.842.36--6.27\< 0.0013.532.13--5.82**\< 0.001**Two-vessel coronary artery disease1.320.67--2.600.430Three-vessel coronary artery disease0.920.42--2.010.838Previous MI0.960.56--1.650.881Previous PCI0.680.42--1.110.121Previous CABG0.880.50--1.560.667Target vessel Left main0.840.42--1.690.623 Left anterior descending0.780.50--1.220.272 Left circumflex1.180.68--2.040.563 Chronic total occlusion1.1420.46--2.830.774 Ostial lesion1.340.83--2.170.236 New-generation DES0.940.56--1.580.821*MI* myocardial infarction, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *DES* drug-eluting stent, *MACE* major adverse cardiac events, *MI* myocardial infarction, *TVR* target vessel revascularization, *LVEF* left ventricular ejection fraction

Discussion {#Sec13}
==========

The principal findings of this analysis are as follows:RA is safe in patients with moderately impaired LV function but is associated with acute hazards in patients with severely depressed LV function.On the long term, LV function has its well-known effect on mortality with a gradual increase in mortality rates with decreasing LVEF.LV function does not affect TVR rates on the long term after RA

Although LV dysfunction is seen in 10--30% of patients undergoing PCI, patients with impaired LVEF are mostly excluded from contemporary PCI trials \[[@CR14], [@CR15]\]. Although recent ESC practice guidelines recommend revascularization in heart failure patients (LVEF \< 35%) with suitable coronary anatomy, this is mainly concluded from the CABG trial \[[@CR16]\]. Therefore, the optimal management and the outcomes of patients with impaired LV function still represent a scientific gap in the setting of complex PCIs.

Data on RA in patients with impaired LV function are scarce, but indicate a higher incidence of adverse events in this patient population. In a recent study by McEntegart et al., RA was associated with a type 4a MI rate of 24% as detected by cardiac magnetic resonance (CMR). Moreover, CMR demonstrated myocardial injury in more than half of the patients, and this injury persisted beyond 6 months in 14% of them \[[@CR17]\]. Indeed, this is a much higher rate than in our analysis, with a total incidence of peri-procedural MI of 2.5%, but one should consider the usage of the CMR with its high sensitivity and specificity for MI detection in combination with troponin increase. In two other recent studies by Watanabe et al. \[[@CR18]\] and Whiteside et al. \[[@CR19]\], slow flow was significantly higher in severely reduced LVEF patients \[defined as ≤ 35% by Watanabe et al. (*n* = 33) and as ≤ 30% by Whiteside et al. (*n* = 18)\].

In line with those studies, we also found that slow flow was more than five-fold higher in patients with severely reduced LVEF (as compared to preserved LVEF) in spite of excluding patients presenting with myocardial infarction from the analysis. These data collectively confirm a strong relationship between LVEF impairment and the risk of slow flow after RA. Previous studies have indeed indicated that coronary flow is closely related to both systolic and diastolic LV function and that slow coronary flow is more frequent in patients with LV dysfunction \[[@CR20], [@CR21]\]. It is worth noting that the operators in our study did not react with glycoprotein IIb/IIIa inhibitors to slow-flow events possibly because of concomitant higher bleeding risks in the cohort with bad ventricular function.

In general, PCI in patients with LVEF \< 35% is associated with higher in-hospital mortality rates \[[@CR22], [@CR23]\] and is considered as a high-risk PCI \[[@CR10], [@CR24]\]. According to the ACCF/AHA/SCAI guidelines for PCI, PMCS is recommended in high-risk PCIs including PCIs in patients with \< LVEF 35% \[[@CR10]\]. Although not specifically addressed by contemporary practice guidelines, hemodynamic support would theoretically convey an even extra benefit in patients with reduced EF undergoing RA, where the hemodynamic consequences of intervention are more profound than in standard PCIs. In our study, PMCS was more frequently used in the severely reduced LVEF group in a total of seven cases, but this relatively small number of patients precluded further valid statistical comparisons.

We observed that there was an association between LV function impairment and higher rates of residual stenosis ≥ 30%. Unlike in general PCI populations where excellent angiographic results can still be achieved in patients with reduced LVEF \[[@CR25], [@CR26]\], it appears that such favorable procedural outcome is less frequent in the setting of very complex lesions requiring RA. A possible explanation for this observation is that a suboptimal angiographic result is more likely accepted in this group of patients. Notably, although the acute angiographic results were suboptimal in patients with reduced LVEF, this did not translate to higher rates of TVR in the long term.

As rotational and orbital atherectomy provide comparable clinical outcomes at short-term follow-up \[[@CR27]\], we find it useful to compare our results with the outcomes of the ORBIT II study \[[@CR28]\]. In contrast to our study, there was no significant difference in the rate of angiographic failure, procedural outcomes, or in-hospital MACE between the reduced LVEF groups (LVEF = 26--40% and LVEF = 41--50%) and preserved LVEF patients (LVEF \> 50%) in the ORBIT II. These results should be interpreted with the knowledge that severe tortuous coronary vessels were excluded from the ORBIT II as well as patients with LVEF ≤ 25%, and that a residual stenosis of less than 50% was considered acceptable. Whether orbital atherectomy is associated with less cardio-depression and microcirculation disturbance in the setting of impaired LV function is unknown, and insights into these questions from ORACLE trial (NCT03021577) are awaited.

In an analysis of more than 230,000 PCI procedures, worsening LVEF independently predicted long-term mortality outcomes \[[@CR29]\]. Moreover, the Dynamic Registry investigators observed similar results with reduced LVEF as a predictor of long-term mortality with no significant differences regarding long-term TVR across different LVEF groups \[[@CR23]\]. In line with these observations in global PCI settings, our analysis showed a stepwise increase in 5-year mortality with decreasing LVEF as well as no association between LVEF and TVR. In the same manner, the rate of 1-year cardiac death in ORBIT II study increased as LVEF decreased, while the rate of 1-year TVR was comparable across the LVEF groups. These observations from our series as well as from the ORBIT II indicate that, as in other PCI settings, the long-term survival after RA mainly depends on LV function.

Lastly, considering the long follow-up period of this study. The rates of procedural outcomes as well as in-hospital MACE were equally distributed among the course of time in our cohort.

Inspite of aging of the population as well as increasing rates of chronic renal impairment and repeated PCI over time course, our peri-procedural outcomes did not worsen over time. That in turn emphasis the evolution in usage of RA in our cohort as the operators became more proficient as time passes.

Limitations {#Sec14}
-----------

First, this is a single-center retrospective study. Second, although this is the largest study to date investigating RA outcomes in patients with reduced LVEF, numbers of adverse events remain relatively small.

Conclusions {#Sec15}
===========

Patients with severely reduced LVEF (≤ 35%) undergoing RA had higher rates of angiographic failure (driven by higher residual stenosis and slow flow) and in-hospital MACE (driven by higher peri-procedural MI). Long term, there was a stepwise increase in all-cause mortality with decreasing LVEF, while the reduction of LVEF was not associated with increased TVR rates.
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